HB0045

HB0045 is a novel anti-CD73 monoclonal antibody therapy developed as a 1:1 mixture of two humanized IgG1 antibodies (HB0038 and HB0039), forming an antibody cocktail that targets and binds to two different epitopes of CD73 on tumor cells. By inhibiting CD73, an ectoenzyme involved in the production of immunosuppressive adenosine in the tumor microenvironment, HB0045 aims to enhance antitumor immune responses. The drug is being investigated primarily for advanced solid tumors, including pancreatic cancer, colorectal cancer, ovarian cancer, and other metastatic or refractory malignancies. It is administered intravenously[2][3][4][6][7].

Other names

anti-CD73 monoclonal antibody HB0045anti-CD-73 monoclonal antibody HB0045anti-CD 73 monoclonal antibody HB0045